Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling

Kun Zhang, Shanshan Zhao, Jialin Du, Lan ZhangFrontiers in Pharmacology 2024 · DOI

TL;DR

Researchers have successfully completed the first-in-human Phase I trial of NH130, a promising new drug candidate for Parkinson’s disease psychosis (PDP). The study demonstrated that NH130 is safe and follows predictable, dose-proportional pharmacokinetics, while also validating a physiologically based pharmacokinetic (PBPK) model that can accurately simulate how the drug behaves in the human body.

What Problem Does This Paper Address?

Parkinson’s disease psychosis (PDP)—characterized by hallucinations and delusions—affects up to 60% of patients and often leads to increased mortality and nursing home placement. Currently, the only FDA-approved drug specifically for PDP is pimavanserin. However, pimavanserin is unavailable in many regions (including China) and carries a "boxed warning" regarding increased mortality in elderly patients and potential heart rhythm issues (QT prolongation).

There is a critical need for new, safe, and accessible treatments. This paper evaluates NH130, a selective serotonin 5-HT2A inverse agonist designed to mimic the benefits of pimavanserin while establishing its own safety and metabolic profile.

Methods

The researchers employed a two-pronged approach:

  1. Clinical Trial: A randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. They enrolled 66 healthy Chinese volunteers across seven dose levels (2 mg to 90 mg). They monitored safety and used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure drug concentrations in the blood over 96 hours.
  2. PBPK Modeling: Using GastroPlus® 9.9 software, the team built a 14-compartment mathematical model. This model integrates physiological data (like organ blood flow) with the drug’s chemical properties (like solubility and permeability) to predict its absorption, distribution, metabolism, and excretion (ADME). This is a sophisticated alternative to standard "black box" statistical modeling, as it accounts for actual human biology.

Datasets

As a first-in-human clinical trial, the primary dataset consisted of original data from 66 healthy Chinese volunteers (54 receiving the active drug and 12 receiving a placebo). The PBPK model was initially built using in vitro (laboratory) data provided by the manufacturer (Jiangsu Nhwa Pharmaceutical Co., Ltd.) and then refined using the Phase I clinical results.

Key Insights and Ideas

  • Predictable Linearity: NH130 showed excellent "dose proportionality." This means if you double the dose, the concentration in the blood doubles predictably. This is a vital characteristic for clinicians because it makes dosing much safer and easier to manage.
  • The Power of PBPK: The PBPK model’s predictions closely matched the actual clinical data (with a "fold error" generally within a 2-fold range). This validates the model as a tool to "skip" some trial-and-error in future studies, such as predicting how the drug might interact with other medications or how it might behave in elderly patients.
  • Serotonin Selectivity: By acting as a selective 5-HT2A inverse agonist, NH130 targets the specific receptors associated with psychosis without interfering with the dopamine receptors needed for motor control—a common pitfall of older antipsychotics that often made Parkinson's physical symptoms worse.

Key Results

  • Safety Profile: No serious adverse events (SAEs) or deaths occurred. Most side effects were mild, such as dizziness or nausea.
  • Absorption and Clearance: The drug reached peak concentration ($T_{max}$) in about 3 to 4.5 hours and had an average half-life ($T_{1/2}$) of approximately 15.7 hours. This suggests the drug is suitable for once-daily dosing.
  • Gender Differences: Interestingly, women appeared more prone to orthostatic hypotension (a drop in blood pressure when standing up) than men at higher doses, an insight that will inform future safety monitoring.
  • Model Validation: The PBPK model successfully simulated the plasma concentration-time curves for most dose groups, confirming its utility for guiding phase II and III development.

Limitations and Future Work

  • Healthy vs. Patient Population: This study used healthy, relatively young volunteers (average age ~30-38). Since PDP affects elderly patients with multiple comorbidities, future trials must confirm these results in the actual target population.
  • Single vs. Multiple Doses: This was a single-dose study. Because PDP requires chronic treatment, multi-dose studies are needed to see if the drug accumulates in the body over time.
  • Small Sample Size: The 2 mg dose group only had two participants, which limits the statistical strength of the data at the lowest end of the spectrum.
  • Metabolite Mystery: While the researchers identified the primary drug behavior, the specific enzymes responsible for breaking down NH130 and the activity of its metabolites remain areas for further investigation.

Summary updated

Abstract

http://www.chinadrugtrials.org.cn/index.html, Identifier CTR20230409.
BibTeX
@inproceedings{zhang2024phase,
  author = {Kun Zhang and Shanshan Zhao and Jialin Du and Lan Zhang},
  title = {{Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1474868},
}
Figure